AbQader Bedil: Donor Ferritin Testing and Iron Care
AbQader Bedil, Medical Laboratory Technologist at French Medical Institute for Mothers and Children- FMIC, Laboratory Incharge at Stanikza Diagnostic clinic, shared a post on LinkedIn:
”Donor Ferritin Testing and Iron Care
Blood donation is generous — but repeated donations quietly drain iron stores. Measuring serum ferritin (not just hemoglobin) is the fastest way to spot iron depletion and act before donors develop symptoms or get deferred. Practical ferritin programs now show you can protect donors and keep the supply stable.
Quick facts:
- Many blood operators now add selective or routine ferritin testing to their donor-wellness programs to identify donors at risk of iron deficiency.
- Expert reviews and working groups recommend ferritin-guided policies (testing, tailored donation intervals, and iron supplementation) as the best way to prevent iron depletion in frequent donors.
- Recent trials show ferritin-guided donation intervals or ferritin-based supplementation significantly raise donors’ ferritin and hemoglobin and reduce iron-deferral rates.
What a practical ferritin program looks like:
- Decide scope: pilot high-risk groups first (premenopausal females, young donors, repeat donors), then expand if capacity allows.
- Pick action thresholds: many programs flag ferritin ≲25 µg/L for intervention (deferred interval or iron offer), but define locally with lab vendors and clinical leads.
- Define actions: short donor pause (eg, 3–6 months), offer oral iron with instructions, or schedule follow-up ferritin testing. Put the action in SOPs and donor letters.
- Measure outcomes: track percent low-ferritin donors, donor return rates, iron-related deferrals, and the program’s effect on supply — iterate from data.
Why this matters:
Ferritin testing is donor-centred and evidence-based: it prevents iron deficiency, reduces unexpected deferrals, and keeps more healthy donors in the pool — that’s a win for donors and patients.”
Stay updated with Hemostasis Today.
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026